Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 5,263 · FY2023 3,189 · FY2024 2,737 — 3-yr total 11,189
Georgian pharmaceutical importer and wholesale distributor. Limited public information available beyond the Reportal filing.
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 19.3% | 18.8% | 20.8% | 22.9% | 22.6% | 24.4% | 29.9% | 29.9% |
| EBITDA Margin | 12.5% | 4.3% | 2.4% | 7.1% | 7.1% | 6.7% | 4.1% | 6.3% |
| EBITDAR | 8,446 | 4,682 | 5,917 | 6,614 | 7,769 | 7,323 | 4,180 | 6,982 |
| EBITDAR Margin | 15.9% | 7.7% | 7.3% | 7.1% | 7.1% | 6.7% | 4.1% | 6.3% |
| EBIT Margin | 11.4% | 3.3% | 1.5% | 3.3% | 3.4% | 2.7% | -0.8% | 1.7% |
| Net Profit Margin | 8.9% | 7.9% | 10.1% | 7.2% | 8.3% | 9.3% | 0.1% | 2.6% |
| Operating Expense % of Sales | 6.8% | 14.5% | 18.4% | 15.8% | 15.4% | 17.7% | 25.8% | 23.5% |
| Returns | ||||||||
| Return on Assets (ROA) | 13.5% | 11.4% | 12.6% | 9.3% | 10.8% | 11.7% | 0.2% | 3.1% |
| Return on Equity (ROE) | 14.9% | 13.0% | 18.8% | 13.4% | 15.5% | 16.1% | 0.3% | 4.8% |
| ROIC [EBIT / Invested Capital] | 21.8% | 8.1% | 2.4% | 5.6% | 6.0% | 4.5% | -1.1% | 2.5% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 0.0% | 0.0% | 21.5% | 20.8% | 19.9% | 18.1% | 21.2% | 19.5% |
| Debt-to-Equity | 0.00x | 0.00x | 0.32x | 0.30x | 0.29x | 0.25x | 0.32x | 0.30x |
| Debt-to-EBITDA | 0.00x | 0.00x | 7.01x | 2.30x | 2.16x | 2.15x | 4.63x | 2.62x |
| Equity-to-Assets | 90.6% | 88.1% | 67.1% | 68.9% | 69.8% | 72.9% | 66.1% | 64.5% |
| Net Debt | -3,861 | -11,792 | 9,533 | 5,310 | 2,438 | 2,722 | 11,600 | 14,819 |
| Cash & Equivalents | 3,861 | 11,792 | 4,308 | 9,828 | 14,283 | 12,941 | 7,652 | 3,447 |
| Total Debt | N/A | N/A | 13,841 | 15,139 | 16,722 | 15,663 | 19,252 | 18,266 |
| Liquidity & working capital | ||||||||
| Current Ratio | 7.34x | 7.62x | 6.39x | 6.91x | 6.40x | 6.99x | 4.63x | 3.36x |
| Quick Ratio | 2.75x | 4.37x | 3.08x | 3.43x | 2.74x | 2.91x | 1.30x | 0.93x |
| Cash Ratio | 1.17x | 2.35x | 0.58x | 1.31x | 1.65x | 1.66x | 0.66x | 0.23x |
| Total Current Assets | 24,266 | 38,238 | 47,042 | 51,688 | 55,427 | 54,681 | 53,727 | 50,341 |
| Total Current Liabilities | 3,304 | 5,019 | 7,365 | 7,482 | 8,667 | 7,818 | 11,595 | 14,987 |
| Inventory | 15,165 | 16,290 | 24,324 | 26,004 | 31,696 | 31,950 | 38,634 | 36,452 |
| Trade Receivables | 4,241 | 4,596 | 9,610 | 5,507 | 4,028 | 3,558 | 2,668 | 4,885 |
| Trade Payables | 3,304 | 5,019 | 7,112 | 5,798 | 7,482 | 7,454 | 11,190 | 14,756 |
| Net Working Capital | 20,962 | 33,219 | 39,676 | 44,206 | 46,760 | 46,863 | 42,132 | 35,354 |
| Net Working Capital % of Revenue | 39.3% | 54.5% | 49.0% | 47.4% | 42.9% | 42.8% | 41.1% | 32.1% |
| Trade Working Capital | 16,102 | 15,866 | 26,822 | 25,712 | 28,242 | 28,054 | 30,111 | 26,582 |
| Trade Working Capital % of Revenue | 30.2% | 26.0% | 33.1% | 27.6% | 25.9% | 25.6% | 29.4% | 24.1% |
| Change in Trade Working Capital | N/A | -236 | 10,955 | -1,110 | 2,530 | -188 | 2,057 | -3,529 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | 2.84x | 3.04x | 2.64x | 2.77x | 2.66x | 2.59x | 1.86x | 2.12x |
| Days Inventory Outstanding (DIO) | 128.7 | 120.1 | 138.4 | 131.9 | 137.1 | 141.0 | 196.3 | 172.2 |
| Receivables Turnover | 12.56x | 13.27x | 8.43x | 16.95x | 27.05x | 30.75x | 38.41x | 22.55x |
| Days Sales Outstanding (DSO) | 29.1 | 27.5 | 43.3 | 21.5 | 13.5 | 11.9 | 9.5 | 16.2 |
| Payables Turnover | 13.02x | 9.87x | 9.02x | 12.41x | 11.28x | 11.09x | 6.42x | 5.24x |
| Days Payable Outstanding (DPO) | 28.0 | 37.0 | 40.5 | 29.4 | 32.4 | 32.9 | 56.8 | 69.7 |
| Cash Conversion Cycle | 129.7 days | 110.6 days | 141.2 days | 124.0 days | 118.3 days | 120.0 days | 148.9 days | 118.6 days |
| Asset Turnover | 1.52x | 1.45x | 1.26x | 1.28x | 1.30x | 1.26x | 1.13x | 1.18x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 4,860 | 7,760 | 2,978 | 12,616 | 8,880 | 11,321 | 6,493 | 12,244 |
| Free Cash Flow (OCF − Capex proxy) | 4,860 | 7,242 | -1,786 | 8,277 | 2,538 | 5,015 | -888 | 8,715 |
| Cash Conversion (OCF / EBITDA) | 73.1% | 292.9% | 150.8% | 191.3% | 114.6% | 155.0% | 156.2% | 175.9% |
| Dividends Declared | 0 | 0 | 0 | 0 | 1,053 | 5,263 | 3,189 | 2,737 |
| Dividend Payout Ratio | 0.0% | 0.0% | 0.0% | 0.0% | 11.6% | 51.8% | 2086.5% | 94.6% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →